• In late February 2026, Ocular Therapeutix highlighted progress in its retinal pipeline and upcoming milestones during a special call and its presentation at the TD Cowen 46th Annual Health Care Conference in Boston, led by CEO Pravin Dugel.
• These updates, alongside ongoing acquisition speculation and strong analyst interest in its hydrogel-based eye disease treatments, have sharpened investor focus on how Ocular’s clinical data could influence its long-term role in ophthalmology.
• We’ll now examine how the recent pipeline-focused conference updates and special call may reshape Ocular Therapeutix’s investment narrative and risk profile.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix today, you need to believe its hydrogel platform, and especially AXPAXLI in wet AMD, can translate strong clinical data into a durable retinal franchise despite ongoing losses and dilution risk. The late February special call and TD Cowen presentation sharpened attention on near term AXPAXLI milestones and regulatory clarity, but did not fundamentally change the key near term catalyst around SOL trials or the central risk of a setback there.

Among the recent developments, the renewed acquisition speculation around a potential Sanofi bid near US$30 per share stands out, because it directly intersects with the same clinical and regulatory catalysts investors are watching. While these rumors remain unconfirmed, they highlight how SOL-1 and SOL-R outcomes, plus FDA feedback, could influence how much value larger pharma might ascribe to Ocular’s retinal pipeline and its hydrogel delivery platform.

Yet against the optimism around AXPAXLI, you should also be aware that insider selling and continued cash burn could leave shareholders more exposed if...

Ocular Therapeutix's narrative projects $192.9 million revenue and $44.8 million earnings by 2028.

Uncover how Ocular Therapeutix's forecasts yield a $24.17 fair value, a 119% upside to its current price.

Exploring Other Perspectives

Before this news, the most bullish analysts were building a far more optimistic case than consensus, assuming revenue could reach about US$251.8 million and earnings around US$58.5 million by 2028, while also flagging high dilution risk from equity raises. As you weigh the latest pipeline headlines, it is worth remembering that these forecasts might be revised up or down, and your view does not need to match any single analyst cohort.

Explore 6 other fair value estimates on Ocular Therapeutix - why the stock might be worth over 7x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.